Superoxide Dismutase Mimetic Chirality for Lower Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing superoxide dismutase enzymes face challenges such as lack of oral activity, short half-lives, immunogenicity, and poor tissue distribution, limiting their therapeutic efficacy in treating inflammatory diseases and conditions.
Innovation Solution
Administration of a superoxide dismutase mimetic compound, specifically Formula (GC4419), which is structurally similar to GC4403 but with mirror image chirality, allowing for higher doses and faster administration without adverse events, catalyzing the conversion of superoxide to hydrogen peroxide and potentially administered alone or in combination with other pharmaceutically active agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural or recombinant superoxide dismutase enzymes are used as therapeutic agents, then superoxide levels are reduced in disease states, but immunogenicity and short half-lives occur
Solution Approach 1:
The patent employs small-molecule superoxide dismutase mimetics (non-proteinaceous catalysts) that replace biological enzymes. These mimetics are chemically stable, non-immunogenic, and can be administered repeatedly without the immunogenicity problems associated with protein-based enzymes. The mimetics fulfill the therapeutic function temporarily until metabolized, then are excreted without triggering immune responses.
Solution Approach 2:
The patent substitutes the biological enzyme system with a chemical catalyst system. The superoxide dismutase mimetics are small organic molecules that catalyze superoxide dismutation through chemical mechanisms rather than biological enzymatic pathways, thereby eliminating immunogenicity while maintaining catalytic activity.
2Reliability
If natural or recombinant superoxide dismutase enzymes are used as therapeutic agents, then superoxide levels are reduced, but oral activity is lacking
Solution Approach 1:
The patent employs small-molecule superoxide dismutase mimetics that are chemically stable and resistant to degradation by digestive enzymes. These mimetics can be administered orally and remain intact through the gastrointestinal tract, achieving therapeutic levels in target tissues without requiring injection or specialized delivery systems.
3Reliability
If natural or recombinant superoxide dismutase enzymes are used as therapeutic agents, then superoxide levels are reduced, but tissue distribution is poor
Solution Approach 1:
The patent employs superoxide dismutase mimetics with specific molecular structures that enable selective accumulation in target tissues with high superoxide production (such as inflamed tissues, tumors, or ischemic areas). The mimetics can be designed with functional groups that facilitate tissue-specific uptake and retention, achieving localized therapeutic effects rather than uniform distribution throughout the body.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
GC4419 exhibits a superior safety profile with at least five-fold improvement over GC4403, enabling higher doses and faster administration while maintaining potency, effectively reducing superoxide levels and treating tissue damage from radiation or chemotherapy.
Implementation Method 1
The enzyme superoxide dismutase catalyzes the conversion of superoxide into oxygen and hydrogen peroxide according to equation (I) (this process is often referred to herein and in the art as dismutation)
Implementation Method 2
The enzyme superoxide dismutase catalyzes the conversion of superoxide into oxygen and hydrogen peroxide according to equation (I) (this process is often referred to herein and in the art as dismutation)
Data Source
AI summary
The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.